Glycomimetics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Glycomimetics Inc
TickerCBIOXXXX
CIK #0001253689
CUSIP38000Q201
SectorLife Sciences - Pharmaceutical Preparations
Address401 Professional Drive, Suite 250, Gaithersburg, MD 20879
Source [EDGAR]
CIK Filing 2011 - 2026
[0001253689] 10-K
[0001253689] 10-Q
[0001253689] 3
[0001253689] 4
[0001253689] 5
[0001253689] 8-K
[0001253689] SC 13D
[0001253689] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Balyasny Asset Management LP Crescent Biopharma Inc [2026-05-15] 0.0
Vestal Point Capital LP Crescent Biopharma Inc [2026-02-17] 0.0
Forgrowth III PA BV Crescent Biopharma Inc [2025-12-11] 0.0
Tang Capital Management LLC Crescent Biopharma Inc [2025-10-09] 0.0
1Globe Capital LLC Crescent Biopharma Inc [2025-08-20] 0.0
FMR LLC Crescent Biopharma Inc [2025-07-08] 0.0
Fairmount Funds Management LLC Glycomimetics Inc [2025-06-23] 0.0
Venrock Healthcare Capital Partners III LP Glycomimetics Inc [2025-06-23] 0.0
Logos Global Management LP Glycomimetics Inc [2024-11-27] 7.8
RA Capital Management LP Glycomimetics Inc [2024-11-06] 0.9
Adage Capital Management LP Glycomimetics Inc [2024-11-04] 7.9
Weinstein Benjamin Glycomimetics Inc [2024-08-14] 0.0
Artal International SCA Glycomimetics Inc [2023-02-13] 12.5
Vanguard Group Inc Glycomimetics Inc [2021-02-10] 5.37
EcoR1 Capital LLC Glycomimetics Inc [2020-07-20] 6.7
Biotechnology Value Fund L P Glycomimetics Inc [2019-08-15] 5.1
Camber Capital Management LP Glycomimetics Inc [2019-08-15] 2013.0
Invesco Ltd Glycomimetics Inc [2019-06-10] 11.0
Price T Rowe Associates Inc /MD/ Glycomimetics Inc [2019-02-14] 8.0
BlackRock Inc Glycomimetics Inc [2019-02-08] 6.6
OppenheimerFunds Inc Glycomimetics Inc [2018-09-06] 10.28
FMR LLC Glycomimetics Inc [2018-02-13] 0.0
Biotechnology Value Fund L P Glycomimetics Inc [2016-06-27] 4.7
Franklin Resources Inc Glycomimetics Inc [2016-02-05] 5.3
Wellington Management Co LLP Glycomimetics Inc [2014-02-10] 10.79
New Enterprise Associates 10 L P Glycomimetics Inc [2014-01-23] 50.3
Form 3/4/5 Filer 2011 - 2026
Scalzo Richard William
Crescent Biopharma Inc
Bispham Barbara Harlin
Im Ellie Eunkyung
McNeill Jonathan
Brumm Joshua T
Lynch Ryan
Pinkas Jan
Kiselak Tomas
Fairmount Funds Management LLC
Harwin Peter Evan
Fairmount Healthcare Fund II L.P.
Violin Jonathan
Moran Susan
Balcom Alexandra
Lubner David Charles
Doughty Christopher Grant
BVF Inc/IL
Biotechnology Value Trading Fund OS LP
BVF Partners L P/IL
Lampert Mark N
BVF GP Holdings LLC
BVF II GP LLC
BVF Partners OS Ltd.
Biotechnology Value Fund L P
Biotechnology Value Fund II LP
BVF I GP LLC
Invus Public Equities Advisors, LLC
Invus Public Equities, L.P.
Debbane Raymond
Invus Global Management, LLC
Siren, L.L.C.
Rock Edwin
Hahn Brian M.
Jackson Scott Thomas
Andrews Patricia S
King Rachel K.
Koenig Scott
Pearson Timothy R
Goldberg Mark Alan
Junius Daniel M
Rath Chinmaya
Johnson Bruce S
Semerjian Harout
Artal Group S.A.
Westend S.A.
Stichting Administratiekantoor Westend
Artal International S.C.A.
Wittouck Amaury
Artal International Management S.A.
Sandell Scott D
Magnani John L.
Girard Armand
Feldman Eric Jay
Thackray Helen M.
Barrett M James
Barris Peter J
NEA Partners 10 L P
New Enterprise Associates 10 L P
Baldwin John J.
Top Franklin H Jr
Henos Michael A
Kerins Patrick J
Viswanathan Ravi
Weller Harry R
Baskett Forest
Kolluri Krishna Kittu
NEA 13 GP, Ltd
NEA Partners 13, Limited Partnership
New Enterprise Associates 13 LP
Drant Ryan D
Mott David M
Gust William M.
Sanofi
Form 13F Holdings
Firm Period DFND Voting Shares
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com